Showing results (271-280 of 933) with videos related to
Sort By:
Pageof 94
Journal of Indian Association of Pediatric Surgeons|June 24, 2024
Foreign Body Ingestion in Children: An Experience of 99 Cases in a Tertiary Care Center in DelhiMeghna Kinjalk, Mehak Sehgal, Simmi K Ratan, et al.Leukemia & Lymphoma|June 15, 2023
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulationLaura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, et al.Journal of Pharmaceutical and Biomedical Analysis|May 25, 2024
Analytical Quality by Design as applied to the development of a SEC-HPLC platform procedure for the determination of monoclonal antibody purity without mobile phase additivesTerezie Cernosek, Matthew Dalphin, Nitin Jain, et al.Journal of Pediatric Urology|October 25, 2008
Protrusion of bladder mucosa in exstrophy mimicking cloacal exstrophyVikas Gupta, Nitin Jain, T C Sadasukhi, et al.Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.Cancer|August 15, 2013
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopeniaPaolo Strati, William Wierda, Jan Burger, et al.Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.Leukemia Research|May 26, 2004
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemiaSrdan Verstovsek, Francis J Giles, Susan O'Brien, et al.Cancer|February 29, 2012
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapyHagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, et al.Pageof 94